Silexion Therapeutics Corp
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
(except share and per share data)
| Six months ended June 30 · Three months ended June 30 | ||||||
|---|---|---|---|---|---|---|
| 2026 · 2025 · 2026 · 2025 | ||||||
| U.S. dollars in thousands · U.S. dollars in thousands | ||||||
| OPERATING EXPENSES: | ||||||
| Research and development (including $176 and $0 from related party for the six-month periods ended June 30, 2026 and 2025, respectively, and including $46 and $0 from related party for the three months period ended June 30, 2026 and 2025, respectively) | $3,582 | $1,608 | $2,212 | $1,018 | ||
| General and administrative (including $282 and $58 from related party for the six-month periods ended June 30, 2026 and 2025, respectively, and including $67 and $37 from related party for the three months period ended June 30, 2026 and 2025, respectively) | 2,847 | 2,326 | 1,468 | 1,266 | ||
| TOTAL OPERATING EXPENSES | 6,429 | 3,934 | 3,680 | 2,284 | ||
| OPERATING LOSS | 6,429 | 3,934 | 3,680 | 2,284 | ||
| Financial expenses (income), net (including $(169) and $229 from related party for the six months period ended June 30, 2026 and 2025, respectively, and including $(154) and $197 from related party for the three months period ended June 30, 2026 and 2025, respectively) | (145) | 301 | (129) | 216 | ||
| LOSS BEFORE INCOME TAX | $6,284 | $4,235 | $3,551 | $2,500 | ||
| INCOME TAX | * | 3 | * | 3 | ||
| NET LOSS | $6,284 | $4,238 | $3,551 | $2,503 | ||
| LOSS PER SHARE, BASIC AND DILUTED | $12.41 | $82.12 | $5.17 | $43.19 | ||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE | 506,202 | 51,613 | ** | 687,353 | 57,952 | ** |
** All share and per share amounts reflect (for periods preceding the relevant reverse share split, on a retroactive basis) 1-for-10 reverse share split effected on May 28, 2026, as discussed in Note 1(d)
F - 5
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.